Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellink_management.jpeg10601102Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-15 08:26:562021-02-15 08:26:56Cellink AB acquires Ginolis Oy for €70m
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
https://european-biotechnology.com/wp-content/uploads/2024/04/Interna.jpg394768Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-09 14:07:332021-02-09 14:07:33InteRNA Technologies secures €18.5m in Series B financing
The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
https://european-biotechnology.com/wp-content/uploads/2024/04/Jens_Spahn_Credits_BMG.jpg16531181Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-09 09:26:452021-02-09 09:26:45German Health Ministry to invest €6.2bn in vaccines
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
https://european-biotechnology.com/wp-content/uploads/2024/04/V-BIO.jpg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-07 17:35:452021-02-07 17:35:45V-Bio Ventures launches second fund at €78m
https://european-biotechnology.com/wp-content/uploads/2024/04/VC_money.jpg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-03 12:44:122021-02-03 12:44:12Abingworth raises US-$465m for new life sciences fund
Swedish AlzeCure appoints CMO
AppointmentsMärta Segerdahl will take over the position as Chief Medical Officer of Swedish AlzeCure Pharma AB on April.
Cellectis and Cytovia in US$760m licence deal
Latest NewsCell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Higher omega-3 level apparently protects from dying from COVID-19
Sponsored PublicationsCellink AB acquires Ginolis Oy for €70m
Latest NewsCellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
Rentschler Biopharma launches gene therapy subsidiary
Latest NewsCDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
InteRNA Technologies secures €18.5m in Series B financing
Latest NewsMicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
German Health Ministry to invest €6.2bn in vaccines
Latest NewsThe German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures launches second fund at €78m
Latest NewsV-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
Latest NewsThe transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
Latest NewsAs rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.